Celldex

Celldex company information, Employees & Contact Information

Explore related pages

Related company profiles:

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.

Company Details

Employees
235
Address
53 Frontage Road, Suite 220,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Hampton, NJ
Looking for a particular Celldex employee's phone or email?

Celldex Questions

News

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewswire

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - Yahoo Finance

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 Yahoo Finance

Leading Biotech Celldex Therapeutics Featured at Morgan Stanley's 23rd Global Healthcare Conference - Stock Titan

Leading Biotech Celldex Therapeutics Featured at Morgan Stanley's 23rd Global Healthcare Conference Stock Titan

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors Yahoo Finance

Profound 71% Mast Cell Reduction: Celldex's Barzolvolimab EoE Trial Reveals Surprising Disconnect in Phase 2 - Stock Titan

Profound 71% Mast Cell Reduction: Celldex's Barzolvolimab EoE Trial Reveals Surprising Disconnect in Phase 2 Stock Titan

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - The Manila Times

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 The Manila Times

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - Yahoo Finance

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 Yahoo Finance

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewswire

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) GlobeNewswire

71% Complete Response: Celldex's Novel CSU Drug Shows Breakthrough Results for All Patient Types - Stock Titan

71% Complete Response: Celldex's Novel CSU Drug Shows Breakthrough Results for All Patient Types Stock Titan

Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped - Healio

Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped Healio

Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD - Dermatology Times

Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD Dermatology Times

Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial - Fierce Biotech

Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial Fierce Biotech

Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU (NASDAQ:CLDX) - Seeking Alpha

Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU (NASDAQ:CLDX) Seeking Alpha

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update The Manila Times

Celldex Announces Upcoming Presentations of Barzolvolimab - GlobeNewswire

Celldex Announces Upcoming Presentations of Barzolvolimab GlobeNewswire

Celldex Therapeutics Announces Proposed Public Offering of Common Stock - Stock Titan

Celldex Therapeutics Announces Proposed Public Offering of Common Stock Stock Titan

Barzolvolimab Shows Long-Term Efficacy in Chronic Spontaneous Urticaria, Improving Patient Quality of Life - AJMC

Barzolvolimab Shows Long-Term Efficacy in Chronic Spontaneous Urticaria, Improving Patient Quality of Life AJMC

Barzolvolimab achieves complete responses in chronic inducible urticaria - Healio

Barzolvolimab achieves complete responses in chronic inducible urticaria Healio

Celldex Appoints Cheryl Cohen and Garry Neil to Board - citybiz

Celldex Appoints Cheryl Cohen and Garry Neil to Board citybiz

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX) - Seeking Alpha

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX) Seeking Alpha

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) Seeking Alpha

Strong association of mast cells with eosinophilic esophagitis‐specific signatures - Alvarado - 2023 - Allergy - Wiley Online Library

Strong association of mast cells with eosinophilic esophagitis‐specific signatures - Alvarado - 2023 - Allergy Wiley Online Library

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study - Nature

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study Nature

Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics (NASDAQ:CLDX) - Benzinga

Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics (NASDAQ:CLDX) Benzinga

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) Seeking Alpha

U.S. Allergy Diagnostics and Therapeutics Market Size to Hit USD 21.20 Billion by 2034 - BioSpace

U.S. Allergy Diagnostics and Therapeutics Market Size to Hit USD 21.20 Billion by 2034 BioSpace

CLDX Stock Price and Chart — NASDAQ:CLDX - TradingView

CLDX Stock Price and Chart — NASDAQ:CLDX TradingView

Celldex Therapeutics (CLDX) Stock Price, News & Analysis - MarketBeat

Celldex Therapeutics (CLDX) Stock Price, News & Analysis MarketBeat

News from Central Jersey’s biotech & pharma industries - Central New Jersey News

News from Central Jersey’s biotech & pharma industries Central New Jersey News

Celldex Therapeutics (CLDX) - Zacks Investment Research

Celldex Therapeutics (CLDX) Zacks Investment Research

Top Celldex Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant